{"acknowledgements and funding": [7, 15, 16, 25, 32], "consent": [52], "material y mtodos": [78], "results": [1, 2, 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 49, 50, 53, 54, 55, 56, 57, 59, 60, 62, 64, 65, 70, 71, 72, 73, 74, 75, 77], "cort regulation of pre- and post-synaptic function": [63], "functional implications of cort-induced increase in nmdar in the adult brain": [63], "appendix 2 functional capacity, physical activity, and well-being questionnaires": [33], "conclusions": [2, 4, 5, 6, 7, 10, 12, 13, 14, 16, 17, 19, 20, 21, 22, 23, 24, 30, 32, 33, 34, 35, 37, 39, 40, 41, 43, 44, 45, 52, 53, 54, 55, 56, 58, 60, 68, 79], "role of gsk-3 in metaplasticity": [68], "symptoms": [60], "data revision": [60], "ghrelin and growth hormone secretagogues": [66], "reference 23": [60], "reference 22": [60], "reference 21": [60], "reference 20": [60], "reference 27": [60], "author details": [2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 47, 48, 50, 52, 53, 55, 56, 57, 58], "reference 25": [60], "reference 24": [60], "demographics": [60], "cort and synaptic plasticity": [63], "background": [2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57], "clinical implications": [73], "the regulation of gsk3 signaling by akt and cell surface receptors": [69], "table 2": [60], "table 1": [60], "concluding remarks": [61], "resultados": [78], "acknowledgments": [61, 62, 64, 65, 66, 67, 68, 69, 71, 72, 73, 74, 75], "appendix 1 cognitive test battery": [33], "anti-apoptotic actions of ghrelin, des-acylated ghrelin and gh secretagogues": [66], "cardiac biomarkers and echocardiographic findings": [60], "possible mechanisms of cort-induced changes in nmdar in the adult brain": [63], "convergence of actions, multiple hits, and target selectivity": [69], "methods": [2, 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 15, 16, 17, 19, 21, 22, 23, 24, 26, 27, 29, 30, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 50, 53, 54, 55, 56, 57, 60, 70, 77], "authors information": [32], "evidence for a role of akt and gsk3 signaling in the behavioral effects of lithium": [69], "gsk-3, ltd, and the implications for learning and memory": [68], "reference 4": [60], "downstream effectors of gsk-3 in synaptic plasticity": [68], "endnotes": [33], "results and discussion": [51], "gsk3, mglurs, and synaptic plasticity": [67], "conclusions and future perspectives": [69], "contribuciones de autora": [78], "funding": [12, 27, 77], "discusin": [78], "animal models of fxs": [67], "reference 3": [60], "method": [20, 49], "ethnic differences": [60], "limitations": [76], "pre-publication history": [6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 41], "potential targets of gsk3 that may contribute to fxs abnormalities": [67], "a role for cb2rs in neuropsychiatric disorders": [61], "acknowledgement and funding": [8], "ghrelin receptor": [66], "introduccin": [78], "clinical trials registration": [74], "glycogen synthase kinase-3": [67], "fragile x syndrome etiology and pathology": [67], "title": [60], "what does the study add to the literature": [77], "reference 18": [60], "reference 19": [60], "reference 16": [60], "reference 17": [60], "reference 14": [60], "reference 15": [60], "reference 12": [60], "reference 13": [60], "reference 10": [60], "reference 11": [60], "trigger event": [60], "role in synaptic plasticity at gabaergic synapses": [68], "references": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 79], "reference 9": [60], "hippocampal cognitive development and maternal care": [63], "reference 5": [60], "reference 6": [60], "reference 7": [60], "reference 1": [60], "reference 2": [60], "case presentation": [52], "statistics": [44], "conflict of interest": [77], "introduction": [1, 36, 37, 38, 52, 58, 59, 60, 62, 63, 64, 65, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 79], "abbreviations": [79], "what is known about this topic": [77], "staging of serotonergic dysfunction in parkinsons disease": [79], "authors contributions": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 77], "reference 8": [60], "inclusion criteria": [60], "patients and methods": [71], "supplementary data": [76], "appendix": [4], "gsk3 and morphology in fx mice": [67], "authors": [60], "role of gsk-3 in ltp and ltd": [68], "upstream regulation of gsk-3 in synaptic plasticity": [68], "exclusion criteria": [60], "involvement of cb1rs in neuropsychiatric disorders": [61], "serotonergic dysfunction and parkinsonsdisease symptomatology": [79], "financiacin": [78], "the neuroprotective actions of ghrelin and ghs": [66], "summary": [67], "future perspectives": [66], "electrocardiography": [60], "study limitations": [60], "methodsdesign": [8, 9, 18, 25, 28, 31, 33, 47, 48], "ethnicity definitions": [60], "abstract": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60], "qu se sabe sobre el tema": [78], "statistical analysis": [60, 71], "direct and indirect regulation of gsk3 by lithium": [69], "reference 26": [60], "clinical trials": [67], "discussion": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 52, 53, 54, 55, 56, 57, 59, 60, 62, 64, 65, 70, 71, 72, 73, 74, 75, 76, 77], "funding sources and potential conflicts of interest": [76], "amelioration of fxs-associated behavioral abnormalities by lithium and other gsk3 inhibitors": [67], "case reports": [76], "conclusion": [3, 11, 15, 18, 26, 27, 28, 29, 36, 38, 42, 49, 51, 57, 72, 73, 74, 76], "materials and methods": [1, 44, 59, 62, 64, 65, 72, 73, 74, 75], "qu aporta el estudio realizado a la literatura": [78], "a distinctive role of cannabidiol cbd in neuropsychiatric disorders": [61], "competing interests": [1, 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59], "recurrence and mortality rates": [60], "figure 1": [60], "acknowledgements": [1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 33, 34, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 50, 52, 53, 54, 56, 57, 58, 59, 77], "the ecb system and eating disorders toward a new therapeutically valid approach": [61], "cort and glutamate receptors": [63], "role in pathological synaptic plasticity": [68], "a brief update on the endocannabinoid ecb system": [61]}
